# Anjay Rastogi

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/anjay-rastogi/

## Facts

| Field | Value |
| --- | --- |
| Citations | 6,503 |
| Field | Dialysis and Renal Disease Management |
| h-index | 38 |
| i10-index | 74 |
| Last Known Institution | FIND |
| OpenAlex ID | https://openalex.org/A5064512017 |
| ORCID iD | 0000-0002-8117-6010 |
| Works | 201 |

## Researcher papers

- [American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis](https://scholariq.org/papers/american-college-of-rheumatology-guidelines-for-screening-treatment-and/)
- [Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial](https://scholariq.org/papers/atrasentan-and-renal-events-in-patients-with-type-2-diabetes-and-chronic-kidney/)
- [A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan](https://scholariq.org/papers/a-practical-guide-for-treatment-of-rapidly-progressive-adpkd-with-tolvaptan/)
- [Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis](https://scholariq.org/papers/finerenone-in-patients-with-chronic-kidney-disease-and-type-2-diabetes-by-sodium/)
- [Four-Week Studies of Oral Hypoxia-Inducible Factor–Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia](https://scholariq.org/papers/four-week-studies-of-oral-hypoxia-inducible-factor-prolyl-hydroxylase-inhibitor/)
- [A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients](https://scholariq.org/papers/a-phase-iii-study-of-the-efficacy-and-safety-of-a-novel-iron-based-phosphate/)
- [Clinical Management of Hyperkalemia](https://scholariq.org/papers/clinical-management-of-hyperkalemia/)
- [A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia](https://scholariq.org/papers/a-phase-3b-randomized-double-blind-placebo-controlled-study-of-sodium-zirconium/)
- [Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients](https://scholariq.org/papers/long-term-effects-of-the-iron-based-phosphate-binder-sucroferric-oxyhydroxide-in/)
- [The Difference Between Cystatin C– and Creatinine-Based Estimated GFR and Associations With Frailty and Adverse Outcomes: A Cohort Analysis of the Systolic Blood Pressure Intervention Trial (SPRINT)](https://scholariq.org/papers/the-difference-between-cystatin-c-and-creatinine-based-estimated-gfr-and/)
- [Targeting B cells in immune-mediated kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference](https://scholariq.org/papers/targeting-b-cells-in-immune-mediated-kidney-diseases-conclusions-from-a-kidney/)

## Researcher topics

- [Dialysis and Renal Disease Management](https://scholariq.org/topics/dialysis-and-renal-disease-management/)
- [Parathyroid Disorders and Treatments](https://scholariq.org/topics/parathyroid-disorders-and-treatments/)
- [Potassium and Related Disorders](https://scholariq.org/topics/potassium-and-related-disorders/)
- [Erythropoietin and Anemia Treatment](https://scholariq.org/topics/erythropoietin-and-anemia-treatment/)
- [Blood Pressure and Hypertension Studies](https://scholariq.org/topics/blood-pressure-and-hypertension-studies/)

## Researcher university

- [FIND](https://scholariq.org/institutions/find/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.